6621-75-6

Basic information

• Product Name: 2,4-DIMETHYLTHIOSEMICARBAZIDE
• Synonyms: 2,4-DIMETHYLTHIOSEMICARBAZIDE;2,4-DIMETHYL-3-THIOSEMICARBAZIDE;2,4-Dimethylthiosemicarbizide;Einecs 229-571-6
• CAS NO: 6621-75-6
• Molecular Formula: C₃H₉N₃S
• Molecular Weight: 119.19
• EINECS: 229-571-6
• Mol File: 6621-75-6.mol
• Article Data: 11

Chemical Properties

• Melting Point: 132-134°C
• Boiling Point: 171.3°C at 760 mmHg
• Flash Point: 57.4°C
• Appearance: /
• Density: 1.159g/cm³
• Vapor Pressure: 1.41mmHg at 25°C
• Refractive Index: 1.577
• CAS DataBase Reference: 2,4-DIMETHYLTHIOSEMICARBAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIMETHYLTHIOSEMICARBAZIDE(6621-75-6)
• EPA Substance Registry System: 2,4-DIMETHYLTHIOSEMICARBAZIDE(6621-75-6)

Safety Data

• Statements: 25
• Safety Statements: 22-36/37/39
• RIDADR: 2811
• Hazardous Substances Data: 6621-75-6(Hazardous Substances Data)

Usage

General Description

2,4-Dimethylthiosemicarbazide is a chemical compound with the formula C3H8N4S. It is a white crystalline solid that is soluble in alcohol and hot water. 2,4-Dimethylthiosemicarbazide is used as a reagent in the synthesis of pharmaceuticals and agrochemicals. It has also been investigated for its potential as an anti-cancer agent. The compound is known to exhibit antimicrobial and antifungal properties, and is used in the formulation of products such as preservatives and fungicides. Additionally, it has been studied for its potential use in the detection and removal of heavy metals from contaminated water sources.

InChI:InChI=1/C3H9N3S/c1-5-3(7)6(2)4/h4H2,1-2H3,(H,5,7)

Upstream product

• 556-61-6 methyl thioisocyanate 
• 60-34-4 methylhydrazine 
• 13037-11-1 S-methyl N-methyl dithiocarbamate 

Downstream Products

• 7112-01-8 1-benzoyl-2,4-dimethylthiosemicarbazide 
• 21185-09-1 p-Methoxy-benzaldehyd-<2.4-dimethyl-thiosemicarbazon> 
• 455-38-9 3-fluorobenzoic acid 
• 110623-33-1 5-(3-fluorophenyl)-2,4-dihydro-2,4-dimethyl-3H-1,2,4-triazole-3-thione 
• 84249-94-5 5,6,7,7a-tetrahydro-1,3-dimethyl-7a-phenyl-1H-pyrrolo[1,2-b][1,2,4]triazole-2(3H)-thione 
• 507448-69-3 6-(4-chloro-2-fluoro-5-methoxy-phenyl)-2,4-dimethyl-5-oxo-3-thioxo-2,3,4,5-tetrahydro-1,2,4-triazine 
• 63847-53-0 methyl-(3-methyl-5,6-diphenyl-3,6-dihydro-[1,3,4]thiadiazin-2-ylidene)-amine; hydrobromide 
• 34257-25-5 2,4-Dimethyl-3-phenyl-[1,2,4]-triazolium-5-thiolat 
• 7112-00-7 2,4-dimethyl-5-phenyl-3H-1,2,4-triazole-3-thione 
• 49572-71-6 1,4-dimethyl-3-thioxo-3,4-dihydro-2H-[1,2,4]triazolium betaine 
• 21885-29-0 2,4-dihydro-2,4-dimethyl-3H-1,2,4-triazole-3-thione 
• 17370-06-8 1,4,5-trimethyl-1,2,4-triazolium-3-thiolate 
• 37526-42-4 2,4,5-trimethyl-2,4-dihydro-[1,2,4]triazole-3-thione 
• 163126-38-3 C₁₁H₁₄N₄OS₂ 

Relevant articles and documents

Identification, synthesis, and biological evaluation of 6-[(6 R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a ]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2 H)-one (AS1940477), a potent p38 MAP kinase inhibitor

Several p38 MAPK inhibitors have been shown to effectively block the production of cytokines such as IL-1β, TNFα, and IL-6. Inhibitors of p38 MAP kinase therefore have significant therapeutic potential for the treatment of autoimmune disease. Compound 2a was identified as a potent TNFα production inhibitor in vitro but suffered from poor oral bioavailability. Structural modification of 2a led to the discovery of tetrahydropyrazolopyrimidine derivatives, exemplified by compound 3, with an improved pharmacokinetic profile. We found that blocking metabolism at the methyl group of the amine and constructing the tetrahydropyrimidine core were important to obtaining compounds with good biological profiles and oral bioavailability. Pursuing the structure-activity relationships of this series led to the discovery of AS1940477 (3f), with excellent cellular activity and a favorable pharmacokinetic profile. This compound represents a highly potent inhibitor of p38 MAP kinase with regard to in vivo activity in an adjuvant-induced arthritis model.

Process for the preparation of 5-aryl-2,4-dialkyl-3H-1,2,4-triazole-3-thiones

The present invention relates to a a novel process for preparing 5-aryl-2,4-dialkyl-3H-1,2,4-triazole-3-thiones which have been shown to have antidepressant activity and are useful in the treatment of Wernicke-Korsakoff syndrome and Alzheimer's disease.

5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers

This invention relates to the enhancement of memory and cognition and the treatment of Alzheimer''s disease and Wernicke-Korsakoff syndrome by administration of 5-(R n -phenyl)-4-alkyl-3H-1,2,4-triazole-3-thiones of the formula STR1 wherein R is halogen, trifluoromethyl, C 1-4 lower alkyl orC 1-4 lower alkoxy,n is zero, 1 or 2, andR 2 represents hydrogen or C 1-3 lower alkyl; andR 4 independently represents C 1-3 lower alkyl.